Clinical Services International (CSI)'s representatives in China are currently attending the DIA China Annual Meeting and it’s been incredibly busy so far with great conversations across the clinical trials community. If you’re attending, connect with the team to discuss global comparator sourcing, clinical trial supplies, and how CSI supports studies worldwide. Set up a meeting with the team: www.csint.com/contact-us

CSI's Managing Director Vanessa Dekou and Associate Project Manager Jessica Ianiro had a great time networking at GCSG - Global Clinical Supplies Group USA in San Diego. Schedule a consultation with CSI's team of experts: www.csint.com/contact-us

Over the past few years, GLP-1 receptor agonists have moved from a niche diabetes treatment to one of the most in-demand drug classes globally. Medicines such as semaglutide and tirzepatide are now widely used not only for type 2 diabetes but increasingly for obesity and metabolic disease. Demand Is Outpacing Supply Global demand for GLP-1 therapies has surged due to increased global trial activity involving GLP-1 comparators, expanding indications and it’s increasing availab

Cold-chain logistics play a pivotal role in pharmaceutical supply, ensuring patient safety and trial continuity. This is especially true in the oncology sector, where most therapies are temperature-sensitive and in high demand, amplifying the need for robust cold-chain infrastructure. Cold-chain logistics refers to the temperature-controlled transport and storage of pharmaceutical products. For biologics, cell and gene therapies and many oncology medications, maintaining a na

The movement of investigational medicinal products (IMPs) and comparators across borders can be a complex undertaking with customs regulations, import/export requirements, and VAT considerations. CSI supports its clients by removing this complexity and ensuring that clinical supplies move efficiently, compliantly and without delay. Global expertise, local execution Our team has extensive experience navigating country-specific regulations, documentation requirements, and impor

CSI’s colleagues in China attended Bio China this week, connecting with innovators across the biotech ecosystem and discussing how we can support efficient clinical development. Next week, the same venue will host CMAC, and our team will be there again. If you're attending, we’d love to meet and explore how CSI can support your clinical supply needs in APAC: www.csint.com/contact-us

Clinical Services International (CSI) will be attending Infarma in Madrid on the 24th–26th March. Get in touch if you’re attending, this is a great opportunity to meet with CSI’s Project Management team to discuss your clinical trial pipeline and comparator sourcing needs. Set up a meeting with us in Madrid here: www.csint.com/contact-us

Clinical Services International (CSI) will be attending CMAC Suzhou from 18–20th March. Our Business Development Managers Chenguang Li and Hayley Zhai from CSI’s Shanghai office will be on site and would be delighted to meet during the conference. If you’d like to discuss your Asia-Pacific clinical supply or comparator sourcing enquiries, we’d love to connect and explore how CSI can support your studies across the region. Looking forward to seeing you in Suzhou! Let’s set up

Book a meeting with Clinical Services International (CSI) ’s team Stephan Mütze and Yasmine Clemson at CTS Barcelona. If you'd like to discuss your clinical trial supply or comparator sourcing needs during the conference, we’d be happy to connect. Book a meeting here: www.csint.com/contact-us

Understanding the Impact of Tariffs on Clinical Trials Recent headlines about proposed US tariffs on European countries highlight the volatility of the global trade environment. As reported this week in Fierce Pharma , potential new duties on several European nations raise questions about the future of US–EU trade relations. This uncertainty can significantly impact the pharmaceutical industry. For sponsors running global clinical trials, this kind of uncertainty translates i

Client: Mid-size biotech conducting multiple clinical trials Challenge: The client required a large quantity of Humira (adalimumab) for several upcoming studies. High costs and limited availability were putting pressure on study budgets and timelines. Solution: CSI leveraged its industry insight and direct relationships with the manufacturer to provide access to a high-quality adalimumab biosimilar. This saved the client a staggering 50% on price. By carefully coordinating so